Core Insights - Arcutis Biotherapeutics, Inc. is set to present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, with a fireside chat scheduled for April 14, 2026, at 11:00 am ET [1] Company Overview - Arcutis is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a portfolio of advanced targeted topicals approved for three major inflammatory skin diseases [2] - The company utilizes a unique dermatology development platform and expertise to create differentiated therapies targeting biologically validated areas, resulting in a robust pipeline for various inflammatory dermatological conditions [2]

Core Insights - Arcutis Biotherapeutics, Inc. will present new data on its ZORYVE (roflumilast) portfolio at the 2026 American Academy of Dermatology Annual Meeting, highlighting advancements in immuno-dermatology [1][2] Clinical Development - The company will present efficacy, safety, and tolerability results from the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% for infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis [2][3] - A five-minute poster presentation will focus on long-term caregiver-reported outcomes from the INTEGUMENT-OLE Phase 3 trial of ZORYVE cream 0.05% in children aged 2 to 5 years with mild to moderate atopic dermatitis [2] - Additional results will include subgroup analyses from the STRATUM Phase 3 trial for seborrheic dermatitis and Psoriasis Area and Severity Index (PASI) outcomes from the DERMIS-1/2 and ARRECTOR trials for plaque psoriasis [2] Product Information - ZORYVE is the leading prescribed branded topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis, utilizing roflumilast, a targeted PDE4 inhibitor that reduces inflammation [5] - ZORYVE cream 0.05% is indicated for mild to moderate atopic dermatitis in pediatric patients aged 2 to 5 years, while ZORYVE cream 0.15% is for patients aged 6 years and older [9] - ZORYVE foam 0.3% is indicated for plaque psoriasis and seborrheic dermatitis in patients aged 12 and 9 years respectively [10] Recognition and Awards - ZORYVE has received multiple awards, including the "2025 Best of Beauty Breakthrough Award" from Allure, and the National Psoriasis Foundation's Seal of Recognition [7] - The American Academy of Dermatology has issued strong recommendations for ZORYVE cream 0.15% for adult patients with mild to moderate atopic dermatitis [7]

Core Insights - Arcutis Biotherapeutics, Inc. is participating in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, with a management fireside chat scheduled for March 2 at 1:50 p.m. ET, available via webcast for 180 days [1] - The company is recognized for its innovative treatments for immune-mediated dermatological conditions, with a portfolio of advanced topical treatments approved for three major inflammatory skin diseases and a strong pipeline targeting various inflammatory dermatological conditions [2] Stock Performance - H.C. Wainwright maintained a "Buy" rating for Arcutis on February 26, 2026, despite a recent stock price decrease, with the stock priced at $27.01 at that time and currently at $26.97, reflecting a decrease of 5.60% or $1.60 [3] - Over the past year, the stock has fluctuated between a high of $31.77 and a low of $11.86, with a current market capitalization of approximately $3.3 billion and a trading volume of 2,129,839 shares on NASDAQ, indicating active investor interest [4]

Core Viewpoint - Arcutis Biotherapeutics, Inc. is actively participating in the TD Cowen 46th Annual Health Care Conference, highlighting its commitment to innovation in immuno-dermatology and its growing portfolio of treatments for inflammatory skin diseases [1][2]. Company Overview - Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on addressing the needs of individuals with immune-mediated dermatological diseases [2]. - The company has developed a portfolio of advanced targeted topicals approved for treating three major inflammatory skin diseases [2]. - Arcutis utilizes a unique dermatology development platform and expertise to create differentiated therapies against biologically validated targets, resulting in a robust pipeline for various inflammatory dermatological conditions [2].

Core Insights - Arcutis Biotherapeutics reported a strong performance in 2025, achieving over 90% year-over-year growth in net product revenue, primarily driven by the demand for ZORYVE and successful product launches [2][5]. Financial Performance - Q4 2025 net product revenue for ZORYVE was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025 [5][6]. - Full year 2025 net product revenue for ZORYVE reached $372.1 million, reflecting a 123% increase over the prior year [5][6]. - Total revenues for Q4 2025 were $129.5 million, compared to $71.4 million for the same period in 2024, driven by strong unit demand growth [9]. - Total revenues for the year ended December 31, 2025, were $376.1 million, compared to $196.5 million for 2024 [9]. Cost and Expenses - Cost of sales for Q4 2025 was $11.7 million, up from $6.9 million in Q4 2024, driven by increased ZORYVE sales volume [10]. - Research and development (R&D) expenses for Q4 2025 were $20.5 million, compared to $14.5 million in Q4 2024, due to higher clinical development costs [11]. - Selling, general, and administrative (SG&A) expenses for Q4 2025 were $79.0 million, compared to $57.6 million in Q4 2024, primarily due to increased sales and marketing expenses [12]. Profitability - The company reported a net income of $17.4 million for Q4 2025, compared to a net loss of $10.8 million in Q4 2024 [13]. - For the full year 2025, the net loss was $16.1 million, significantly improved from a net loss of $140.0 million in 2024 [13]. Cash Flow and Guidance - Arcutis achieved positive cash flow with $26.2 million from operations in Q4 2025, driven by ZORYVE sales growth [15]. - The company raised its 2026 full-year net product sales guidance to between $480 million and $495 million [16]. Product Development and Market Access - ZORYVE cream 0.05% was launched for treating atopic dermatitis in children aged 2 to 5 years following FDA approval [6]. - The company secured Medicare access for ZORYVE starting January 2026, with approximately one in three Medicare patients having non-preferred access [6]. - Positive topline data was reported for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in infants with atopic dermatitis, with an sNDA submission expected in Q2 2026 [5][6].

Core Viewpoint - Arcutis Biotherapeutics, Inc. has launched the "Free to Be Me" awareness campaign featuring professional golfer Max Homa to encourage individuals with seborrheic dermatitis to seek long-term treatment options [1][2]. Company Overview - Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a commitment to addressing the needs of individuals with immune-mediated dermatological diseases [13]. - The company has developed ZORYVE, a topical foam treatment for seborrheic dermatitis, which is steroid-free and suitable for various skin types [6][7]. Product Information - ZORYVE foam 0.3% is indicated for treating seborrheic dermatitis in adults and children aged 9 and older [10]. - Clinical trials showed that 77% of individuals using ZORYVE foam achieved clear or almost clear skin after 8 weeks, compared to 53% using an inactive foam [3][4]. - The product provides rapid skin clearance and significant itch relief, with nearly 63% of users reporting significant itch relief at Week 8 [4]. Clinical Efficacy - ZORYVE foam has been recognized for its clinical impact, receiving multiple awards, including the "2025 Best of Beauty Breakthrough Award" from Allure [8]. - The treatment is formulated to be safe and well-tolerated, with common side effects including common cold (1.5%), nausea (1.3%), and headache (1.1%) [5][11]. Campaign Details - The "Free to Be Me" campaign aims to share real experiences of individuals with inflammatory skin conditions to empower them to discuss treatment options with healthcare providers [9].

Core Viewpoint - Arcutis Biotherapeutics, Inc. has launched the "Free to Be Me" awareness campaign featuring professional golfer Max Homa to raise awareness about seborrheic dermatitis and encourage patients to seek long-term treatment options [1][2][12] Company Overview - Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a commitment to addressing the needs of individuals with immune-mediated dermatological diseases [16] Product Information - ZORYVE (roflumilast) foam 0.3% is a steroid-free topical treatment for seborrheic dermatitis, effective in reducing itching, redness, and flaking [4][10] - Clinical trials show that 77% of patients using ZORYVE foam achieved clear or almost clear skin after 8 weeks, compared to 53% using an inactive foam [7][8] - The product is indicated for adults and children aged 9 and older, and is designed to be safe and well-tolerated, with common side effects including common cold (1.5%), nausea (1.3%), and headache (1.1%) [9][13] Market Context - Approximately 10 million Americans suffer from seborrheic dermatitis, a chronic inflammatory skin disease that can significantly impact quality of life [4] - ZORYVE foam is recognized as the number one prescribed branded topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis [10][11] Campaign Details - The "Free to Be Me" campaign aims to share real experiences of individuals with inflammatory skin conditions to empower them to discuss treatment options with healthcare providers [12]

Core Viewpoint - Arcutis Biotherapeutics has terminated its promotion agreement with Kowa Pharmaceuticals for ZORYVE, and will take over the sales and promotion responsibilities in the pediatric and primary care markets [1][2][3] Group 1: Agreement Termination - The promotion agreement with Kowa Pharmaceuticals was mutually terminated on January 23, 2026, which involved the sales and promotion of ZORYVE to primary care physicians and pediatricians in the U.S. [1] - Under the termination agreement, Kowa will cease all sales and promotions of ZORYVE, and Arcutis will not be required to make any further payments [3] Group 2: Future Plans - Arcutis plans to assume responsibility for the sales and promotion of ZORYVE in pediatric and primary care settings, with further updates expected during the Q4 earnings call on February 25, 2026 [2] - The company is also expanding its dermatology salesforce to enhance ZORYVE prescriptions in dermatology practices [2] Group 3: Product Information - ZORYVE cream is indicated for the treatment of mild to moderate atopic dermatitis in pediatric patients aged 2 to 5 years and in patients aged 6 years and older [4] - ZORYVE foam is indicated for the treatment of plaque psoriasis and seborrheic dermatitis in patients aged 12 years and older and 9 years and older, respectively [5] Group 4: Safety Information - ZORYVE is contraindicated in patients with moderate to severe liver impairment and has flammability warnings due to its propellant [6] - Common adverse reactions for ZORYVE cream and foam include upper respiratory tract infection, diarrhea, headache, and nausea, with varying percentages across different age groups and formulations [7][8][9][10] Group 5: Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a growing portfolio of advanced targeted topicals [11]

Core Insights - Arcutis Biotherapeutics, Inc. is focused on sustainable growth through its innovative dermatology products, particularly the ZORYVE franchise, which has shown significant commercial momentum [2][5][6] Financial Performance - For Q3 2025, Arcutis reported net product revenue of $99.2 million, marking a 122% increase year-over-year and a 22% increase sequentially from Q2 2025 [5][7][9] - The revenue breakdown includes $30.5 million from ZORYVE cream 0.3%, $18.9 million from ZORYVE cream 0.15%, and $49.8 million from ZORYVE topical foam 0.3% [9] - The company anticipates full-year net product sales for 2026 to be between $455 million and $470 million [14] Product Development and Pipeline - ZORYVE is a potent PDE4 inhibitor approved for treating plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, with ongoing Phase 2 studies for vitiligo and hidradenitis suppurativa [3][4][6] - The company is also advancing its clinical pipeline with ARQ-234, a potential biologic treatment for atopic dermatitis [8] Cost and Expenses - Cost of sales for Q3 2025 was $8.7 million, up from $5.5 million in Q3 2024, reflecting increased sales of ZORYVE [10] - Research and development expenses remained stable at $19.6 million, while selling, general, and administrative expenses rose to $62.4 million due to increased commercialization efforts [11][12] Profitability - Arcutis achieved a net income of $7.4 million, or $0.06 per share, compared to a net loss of $41.5 million in Q3 2024 [13][24]

Core Insights - Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3% for treating plaque psoriasis in patients aged 12 and older, marking a significant advancement in immuno-dermatology [1][5] - ZORYVE foam is a once-daily, steroid-free treatment that is now widely available, addressing the needs of nearly 9 million people in the U.S. living with plaque psoriasis, particularly those with scalp involvement [2][5] Product Details - ZORYVE foam demonstrated significant improvements in clinical trials, achieving Scalp-Investigator Global Assessment (S-IGA) Success in 66.4% of patients compared to 27.8% for the vehicle foam at Week 8 [8] - The foam also provided rapid itch relief, with 65.3% of patients experiencing a clinically significant reduction in scalp itch compared to 30.3% for the vehicle [10] - ZORYVE is indicated for both plaque psoriasis and seborrheic dermatitis, with a focus on hard-to-treat areas such as the scalp and body [14][15] Clinical Trial Results - The approval was supported by positive results from Phase 2 and pivotal Phase 3 trials, enrolling 736 adults and adolescents with mild to severe plaque psoriasis [7] - In the ARRECTOR study, 45.5% of individuals treated with ZORYVE foam achieved Body-IGA Success compared to 20.1% for the vehicle foam at Week 8 [8] - The treatment was well tolerated, with low incidence of adverse events, primarily mild to moderate in severity [12] Market Context - The approval of ZORYVE foam is the fifth for the product in less than three years, highlighting Arcutis' commitment to addressing urgent needs in dermatology [3][5] - The company aims to provide predictable access to ZORYVE through programs that assist patients with adherence and reduce out-of-pocket costs [4][21] Future Engagement - Arcutis will host a virtual Key Opinion Leader Event on June 2, 2025, to discuss the treatment landscape for plaque psoriasis, featuring insights from a leading expert [4][5]